Related Experiment Video
Updated: Jun 13, 2026
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease
S F Bortvedt1, J A McLear, A Messer
1University of Portland, Biology Department, Portland, Oregon 97203, USA.
Insights
Combining cystamine drug treatment with an anti-Huntingtin (HTT) intrabody in a Drosophila model of Huntington's disease (HD) shows therapeutic potential. The timing of this combination therapy impacts whether neurodegeneration or longevity is more effectively improved.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is a fatal neurodegenerative disorder.
- It stems from polyglutamine repeat expansion in the Huntingtin gene (HTT).
- Previous treatments showed incomplete suppression of HD pathology.
Purpose of the Study:
- To investigate if a combination therapy of cystamine and an anti-HTT intrabody enhances Huntington's disease (HD) pathology rescue in Drosophila.
- To determine the effect of treatment timing on therapeutic outcomes.
Main Methods:
- Utilized a Drosophila model of Huntington's disease (HD).
- Administered cystamine orally and expressed an anti-HTT intracellular antibody (intrabody) in the nervous system.
- Varied the timing of cystamine and intrabody administration (adults only vs. larval and adult stages).
Main Results:
- Treating adult HD flies with both cystamine and the intrabody significantly rescued photoreceptor neurodegeneration but did not improve longevity.
- Administering cystamine during both larval and adult stages significantly improved longevity but not photoreceptor survival.
- Demonstrated that combination therapy effectiveness is dependent on administration timing.
Conclusions:
- Cystamine-intrabody combination therapies offer a promising strategy for Huntington's disease (HD) treatment.
- Optimizing administration protocols is crucial for maximizing therapeutic benefits, such as reducing neurodegeneration and prolonging survival.
- This study highlights the potential for combinatorial drug and gene-based approaches in neurodegenerative disease therapy.
Abstract:
Huntington's disease (HD) is a lethal, neurodegenerative disorder caused by expansion of the polyglutamine repeat in the Huntingtin gene (HTT), leading to mutant protein misfolding, aggregation, and neuronal death. Feeding a Drosophila HD model cystamine, or expressing a transgene encoding the anti-htt intracellular antibody (intrabody) C4-scFv in the nervous system, demonstrated therapeutic potential, but suppression of pathology was incomplete. We hypothesized that a combinatorial approach entailing drug and intrabody administration could enhance rescue of HD pathology in flies and that timing of treatment would affect outcomes. Feeding cystamine to adult HD flies expressing the intrabody resulted in a significant, additional rescue of photoreceptor neurodegeneration, but no additional benefit in longevity. Feeding cystamine during both larval and adult stages produced the converse result: longevity was significantly improved, but increased photoreceptor survival was not. We conclude that cystamine-intrabody combination therapies can be effective, reducing neurodegeneration and prolonging survival, depending on administration protocols.
